首页 新泰医药(usMDGL)-基本信息

新泰医药(usMDGL)-基本信息

日报更新时间:

周报更新时间:04-11 03:39

行情信息

今开价:117.23

最高价:118.36

成交量:93106.0

昨收价:117.02

最低价:114.5

最新价:117.02

行情图标
概要信息

中文名称:新泰医药


英文名称:Madrigal Pharmaceuticals


简介:Madrigal Pharmaceuticals, Inc.于2000年3月成立并在2001年7月开始运营


电话:1-484-3809263


最新量化综合结论
百科信息
  • 相关网站
  • 员工交易记录
  • 持股信息
  • 领导人信息

交易日期 交易人 职位 类型 交易份额 价格
2016-07-21 Craves (Frederick B) Director and Beneficial Owner Buy 296067 --
2016-07-21 Taub (Rebecca A) Officer, Director and Beneficial Owner Buy 729066 --
2016-07-21 Rieder (Wendy E) Officer Buy 25714 --
2016-07-21 Rieder (Wendy E) Officer Sell 8550 9.48
2016-07-21 Schneebaum (Marc R) Chief Financial Officer Buy 25714 --
2016-07-21 Schneebaum (Marc R) Chief Financial Officer Sell 8548 9.48
2016-07-21 Schor (Chen) Officer and Director Buy 42857 --
2016-07-21 Schor (Chen) Officer and Director Sell 14250 9.48
2016-07-21 Taub (Rebecca A) Officer, Director and Beneficial Owner Buy 404132 --
2016-07-21 Taub (Rebecca A) Officer, Director and Beneficial Owner Buy 28740 --
2016-07-21 Craves (Frederick B) Director and Beneficial Owner Buy 5538474 --
2016-07-21 Craves (Frederick B) Director and Beneficial Owner Buy 119380 --
2016-07-21 Friedman (Paul A) Chief Executive Officer Buy 729066 --
2016-07-21 Friedman (Paul A) Chief Executive Officer Buy 146 --
2016-07-21 Friedman (Paul A) Chief Executive Officer Buy 143557 --
2016-07-21 Schneebaum (Marc R) Chief Financial Officer Buy 22969 --
2015-12-31 Morenstein (Scott D) Director Buy 17857 --
2015-12-13 Gollust (Keith R) Director Sell 300000 0.32
2015-12-10 Gollust (Keith R) Director Sell 300000 0.37
2015-12-08 Gollust (Keith R) Director Sell 145892 0.38
2015-12-07 Kovner (Bruce) Director and Beneficial Owner Sell 873624 0.37
2015-12-07 Kovner (Bruce) Director and Beneficial Owner Sell 496015 0.37
2015-12-07 Gollust (Keith R) Director Sell 300000 0.38
2015-12-06 Kovner (Bruce) Director and Beneficial Owner Sell 36 0.41
2015-12-06 Gollust (Keith R) Director Sell 300000 0.39
2015-12-06 Gollust (Keith R) Director Sell 300000 0.39
2015-12-03 Kovner (Bruce) Director and Beneficial Owner Sell 55629 0.41
2015-12-03 Kovner (Bruce) Director and Beneficial Owner Sell 97978 0.41
2015-12-02 Kovner (Bruce) Director and Beneficial Owner Sell 95040 0.41
2015-12-02 Kovner (Bruce) Director and Beneficial Owner Sell 167394 0.41
第 页, 共 3 页 首页 上页 下页 末页

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Goldman Sachs Group Inc 122088 0.79% 34378 39.20% 2019-03-31
SSGA Funds Management Inc 454327 2.95% 8165 1.83% 2019-07-31
BlackRock Inc 522540 3.39% -10470 -1.96% 2019-03-31
State Street Corporation 566362 3.67% -34065 -5.67% 2019-03-31
Vanguard Group Inc 781276 5.07% 34300 4.59% 2019-03-31
Healthcor Management LP 891990 5.79% 203100 29.48% 2019-03-31
Baker Bros Advisors LP 1169278 7.58% -- -- 2019-03-31
Capital Research Global Investors 1664452 10.80% -- -- 2019-03-31
Capital Research and Management Company 1683052 10.91% 18600 1.12% 2019-07-31
Armistice Capital, LLC 425000 2.76% 425000 -- 2019-03-31
Jennison Associates LLC 311020 2.02% 29949 10.66% 2019-03-31
venBio Select Advisor LLC 310000 2.01% 85000 37.78% 2019-03-31
Northern Trust Investments Inc 141689 0.92% 2338 1.68% 2019-07-31
PGIM Investments LLC 149779 0.97% -48812 -24.58% 2019-07-31
Vanguard Investments Australia Ltd 202284 1.31% 14179 7.54% 2019-07-31
Rock Springs Capital Management LP 255250 1.66% 14250 5.91% 2019-03-31
T. Rowe Price Associates, Inc. 261537 1.70% 518 0.20% 2019-03-31
Marshall Wace North America LP 282602 1.83% 282602 -- 2019-03-31
BlackRock Fund Advisors 289463 1.88% 6086 2.15% 2019-07-31
AllianceBernstein L.P. 309605 2.01% 3471 1.13% 2019-03-31
BlackRock Asset Management Canada Ltd 163455 1.06% 30 0.02% 2019-05-31
Geode Capital Management, LLC 181032 1.17% 95052 110.55% 2018-12-31
Northern Trust Corp 96271 0.62% 1247 1.31% 2019-03-31
Northern Trust Investments N A 95024 0.62% -7804 -7.59% 2018-12-31
Fidelity Management & Research Company 92700 0.60% -67689 -42.20% 2019-03-31
Victory Capital Management Inc. 193698 1.26% 9451 5.13% 2018-09-30
OppenheimerFunds Inc 95830 0.62% -39110 -28.98% 2018-09-30
OFI Global Asset Management, Inc. 107351 0.70% 209 0.20% 2018-11-30
Capital World Investors 130500 0.85% 73500 128.95% 2018-06-30
BlackRock Institutional Trust Company NA 199369 1.30% 58436 41.46% 2018-06-30
Polar Capital LLP 200000 1.30% 20000 11.11% 2018-03-31
EcoR1 Capital, LLC 199500 1.30% 199500 -- 2018-06-30
AllianceBernstein LP 176228 1.15% -98126 -35.77% 2018-06-30
RS Investment Management Co. LLC 105776 0.69% -9520 -8.26% 2018-06-30
Boxer Capital LLC 95000 0.62% 95000 -- 2018-06-30
Lord, Abbett & Co LLC 92193 0.60% 31993 53.14% 2018-06-30
State Street Corp 342506 2.23% -117865 -25.60% 2018-06-30
Fidelity Management and Research Company 62774 0.41% -158057 -71.57% 2018-06-30
Citadel Advisors Llc 190653 1.34% -190674 -50.00% 2018-03-31
Millennium Management LLC 92291 0.65% 88386 2263.41% 2018-03-31
Invesco PowerShares Capital Mgmt LLC 118762 0.83% 118762 -- 2018-03-31
Adage Capital Partners Gp LLC 50000 0.33% -200000 -80.00% 2018-06-30
Perceptive Advisors LLC 142522 1.00% -46371 -24.55% 2018-03-31
Prudential Investments LLC 132517 0.93% -- -- 2018-05-31
Ascend Capital LLC 117494 0.83% 43979 59.82% 2017-12-31
Point72 Asset Management, L.P. 120000 0.84% 120000 -- 2017-12-31
Sectoral Asset Management Inc 50649 0.36% 13799 37.45% 2018-03-31
Renaissance Technologies Corp 87587 0.62% -39700 -31.19% 2017-12-31
Bogle Investment Management L P 95191 0.67% 95191 -- 2017-12-31
FMG LLC 36964 0.30% 13940 60.55% 2018-01-31
SEI Investments Management Corp 20303 0.16% -1102 -5.15% 2018-02-28
AST Investment Services Inc 19020 0.15% -- -- 2018-01-31
D. E. Shaw & Co LP 24992 0.20% 24992 -- 2017-12-31
Jackson National Asset Management LLC 23870 0.19% 23870 -- 2017-12-31
Shikiar Asset Management Inc 23141 0.19% -- -- 2017-12-31
Alps Advisors Inc 15002 0.11% -- -- 2018-02-08
Deutsche Bank AG 41446 0.33% 28722 225.73% 2017-09-30
Columbia Mangmt Investment Advisers, LLC 20051 0.16% 20051 -- 2017-12-31
VHCP Management II, LLC 30000 0.24% 30000 -- 2017-09-30
Sio Capital Management, LLC 26958 0.22% 26958 -- 2017-09-30
Charles Schwab Investment Management Inc 13800 0.11% -- -- 2017-09-30
Virtus ETF Advisers LLC 4382 0.06% -- -- 2017-12-21
TIAA-CREF Investment Management LLC 8304 0.07% 950 12.92% 2017-09-30
Bay City Capital LLC 5657854 4.11% 5657854 -- 2016-07-22
Goldman, Sachs & Co. 12043 0.10% 12043 -- 2016-09-30
Vericimetry Advisors LLC 4400 0.04% 4400 -- 2016-09-30
Mellon Capital Management Corporation 3353 0.03% 3214 2312.23% 2016-12-31
Panagora Asset Management Inc 3279 0.03% 3279 -- 2016-09-30
Guggenheim Funds Investment Advisors LLC 2581 0.02% -- -- 2017-02-08
Group One Trading, LP 1824 0.02% 1824 -- 2016-09-30
Connor Clark & Lunn Financial Group 848 0.01% -1 -0.12% 2017-01-31
BlackRock Advisors LLC 558 -- 558 -- 2016-09-30
Kinetics Asset Management LLC 514 -- 514 -- 2016-09-30
Caxton Corp 506738 4.38% 506738 -- 2016-09-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Vanguard Small Cap Value Index Fund 133709 0.87% -4847 -3.50% 2019-06-30
T. Rowe Price Small-Cap Stock Fund 39701 0.26% -600 -1.49% 2019-06-30
PGIM Jennison Health Sciences Fund 142508 0.92% -- -- 2019-06-30
iShares Russell 2000 ETF 175434 1.14% 5342 3.14% 2019-07-30
Vanguard Total Stock Market Index Fund 199781 1.30% 14194 7.65% 2019-06-30
Vanguard Small Cap Index 220214 1.43% -958 -0.43% 2019-06-30
SPDR 446091 2.89% 6930 1.58% 2019-07-31
American Funds SMALLCAP World Fund 732647 4.75% -- -- 2019-06-30
American Funds Growth Fund of Amer 819405 5.31% 138400 20.32% 2019-06-30
Vanguard Extended Market Index Fund 115454 0.75% -111 -0.10% 2019-06-30
AB Discovery Growth Fund 75420 0.49% 1980 2.70% 2019-06-30
American Funds New Economy Fund 73000 0.47% -- -- 2019-06-30
Fidelity 39898 0.26% -- -- 2019-06-30
Candriam Eqs L Biotechnology 41450 0.27% -- -- 2019-06-30
Direxion Daily S&P Biotech Bull 3X Shrs 43237 0.28% 11726 37.21% 2019-04-30
American Funds IS 58000 0.38% -119800 -67.38% 2019-06-30
AB Small Cap Growth Portfolio 64090 0.42% 4390 7.35% 2019-06-30
Invesco Dynamic Biotech & Genome ETF 69929 0.45% 3040 4.54% 2019-07-31
iShares Russell 2000 Growth ETF 71893 0.47% 1064 1.50% 2019-07-30
T. Rowe Price Health Sciences Fund 72456 0.47% -500 -0.69% 2019-06-30
Polar Capital Biotechnology Fund 43550 0.28% -6450 -12.90% 2019-05-31
iShares US Small Cap ETF (CAD-Hedged) 140616 0.91% -234 -0.17% 2019-05-30
DWS Biotech 48000 0.31% 35995 299.83% 2019-04-30
Vanguard Small Cap Index Fund 221757 1.44% 594 0.27% 2019-04-30
Vanguard Market Neutral Fund 57910 0.38% 30383 110.38% 2018-12-31
Vanguard Strategic Equity Fund 81387 0.53% -- -- 2018-12-31
ALPS Medical Breakthroughs ETF 35947 0.23% -- -- 2019-02-28
RI CBF Dir AllianceBern Small Cap Gr 56170 0.36% 1190 2.16% 2019-01-31
RI CBF Dir AllianceBern Discovery Gr 74350 0.48% 140 0.19% 2019-01-31
VA CollegeAmerica The Gr Fd of Amer 681005 4.42% 681005 -- 2018-12-31
VA CollegeAmerica SMALLCAP Wld Fd 732647 4.75% -- -- 2018-12-31
VA CollegeAmerica The New Economy Fd 73000 0.47% 73000 -- 2018-12-31
Interfund Equity USA 47781 0.31% -3334 -6.52% 2019-01-31
iShares US Pharmaceuticals ETF 34856 0.23% -- -- 2019-01-31
T. Rowe Price Mid-Cap Growth Fund 75000 0.49% -- -- 2018-09-30
PGIM Jennison Small Company Fund 48875 0.32% -- -- 2018-11-30
Victory RS Small Cap Growth Fund 96000 0.62% 10340 12.07% 2018-09-30
Oppenheimer International Small-Md Co Fd 95010 0.62% -- -- 2018-10-31
Lord Abbett Developing Growth Fund 43528 0.28% -490 -1.11% 2018-07-31
Eventide Healthcare & Life Sciences Fund 46000 0.30% 21000 84.00% 2018-06-30
RI CBF AllianceBern Discovery Growth 54020 0.35% 6060 12.64% 2018-09-30
Vanguard Strategic Equity Inv 45406 0.30% 45406 -- 2018-06-30
Lord Abbett Developing Growth A 43528 0.28% -490 -1.11% 2018-07-31
RI CBF AllianceBern Discovery Gr RA 42990 0.28% 3430 8.67% 2018-07-31
BlackRock Health Sciences Opps Inv A 38200 0.25% -- -- 2018-07-31
Fidelity Spartan 36963 0.24% -- -- 2018-07-31
AB Small Cap Growth A 34230 0.22% 2770 8.80% 2018-07-31
Delaware Healthcare A 28000 0.18% 4600 19.66% 2018-07-31
T. Rowe Price QM US Small-Cap Growth Eq 22800 0.15% 22800 -- 2018-06-30
Eventide Healthcare & Life Sciences A 46000 0.30% 21000 84.00% 2018-06-30
iShares Russell 2000 Growth 56038 0.36% -54 -0.10% 2018-09-12
VA CollegeAmerica Smcap World 529E 789647 5.14% 789647 -- 2018-06-30
T. Rowe Price Health Sciences 235233 1.53% 235233 -- 2018-06-30
Vanguard Total Stock Mkt Idx 209285 1.36% 230 0.11% 2018-07-31
Vanguard Extended Market Idx Inv 109114 0.71% 1400 1.30% 2018-07-31
Prudential Jennison Health Sciences A 98149 0.64% -- -- 2018-07-31
Oppenheimer International Small-Mid Co A 95010 0.62% -38790 -28.99% 2018-07-31
RS Small Cap Growth A 85660 0.56% -7160 -7.71% 2018-06-30
T. Rowe Price Mid-Cap Growth 75000 0.49% 75000 -- 2018-06-30
AXA/AB Small Cap Growth IB 20740 0.13% -12640 -37.87% 2018-06-30
AST Small Cap Growth Opportunities 18760 0.13% 990 5.57% 2018-05-31
T. Rowe Price Instl Mid-Cap Equity Gr 18408 0.13% 18408 -- 2018-06-30
RS Technology A 16946 0.12% -1760 -9.41% 2018-06-30
Vanguard Health Care ETF 15562 0.11% 1116 7.73% 2018-06-30
MassMutual Select Mid Cap Gr Eq II A 14363 0.10% 14363 -- 2018-06-30
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 14233 0.10% 2921 25.82% 2018-06-30
Lord Abbett Micro Cap Growth I 13424 0.09% -245 -1.79% 2018-05-31
Oppenheimer International Diversified A 14493 0.10% 318 2.24% 2018-05-31
BlackRock Extended Equity Market K 14197 0.10% 2575 22.16% 2018-06-30
Principal SmallCap Growth I Instl 19498 0.14% 1530 8.52% 2018-05-31
Vanguard Instl Ttl Stk Mkt Idx InstlPls 11030 0.08% -- -- 2018-05-31
JNL Multi-Manager Small Cap Growth B 23200 0.16% -670 -2.81% 2018-03-31
Fidelity Advisor 53781 0.38% -102819 -65.66% 2018-01-31
iShares Micro-Cap 13133 0.10% -- -- 2018-06-21
BioShares 9845 0.08% -- -- 2018-06-14
PowerShares Dynamic Biotech & Genome ETF 50334 0.41% -- -- 2018-05-17
PowerShares DWA SmallCap Momentum ETF 39268 0.24% -- -- 2018-03-22
PowerShares DWA Healthcare Momentum ETF 17225 0.14% -- -- 2018-03-08
Active Port 12103 0.10% -7948 -39.64% 2018-01-31
AXA/Lord Abbett Micro Cap K 12973 0.10% -- -- 2018-01-31
SEI Small Cap A (SIMT) 9285 0.07% 2531 37.47% 2018-01-31
CREF Stock R1 24189 0.19% 439 1.85% 2017-12-31
Dreyfus Select Managers Small Cap Gr A 13483 0.11% 13483 -- 2017-12-31
SEI Small Cap II A (SIIT) 6478 0.05% 6478 -- 2017-12-31
Schwab Small Cap Index 13800 0.11% -- -- 2017-09-30
BlackRock Russell 2500 6210 0.05% 6107 5929.13% 2017-12-31
BlackRock Russell 2000 6342 0.05% 1522 31.58% 2017-12-31
The Vanguard Russell 2000 Growth Index 6856 0.05% -- -- 2017-11-30
TIAA-CREF Small-Cap Blend Idx Inst 4811 0.04% -- -- 2017-11-30
BNY Mellon EB DL Mkt Completion 3211 0.03% 3211 -- 2016-12-31
Wilshire Micro-Cap ETF 2581 0.02% -- -- 2017-02-08
Vanguard Balanced Index Inv 2620 0.02% -- -- 2016-12-31
The Vanguard Total Stock Market Index 1452 0.01% -- -- 2016-12-31
Vericimetry U.S. Small Cap Value 4400 0.04% 4400 -- 2016-09-30
iShares Core S&P Total US Stock Mkt 632 0.01% -- -- 2017-02-07
Master Extended Market Index Series 558 -- -- -- 2016-12-31
Kinetics Medical No Load 514 -- 514 -- 2016-09-30
BNY Mellon Market Completion Fund UC1 142 -- 3 2.16% 2016-12-31
Vanguard Russell 3000 ETF 46 -- -- -- 2016-12-31
SSgA U.S. Total Market Index Fd Class I 682 0.01% 682 -- 2016-09-30

Fred Bernard Craves Dr. Fred B. Craves is a Managing Director at Bay City Capital LLC and Chairman at Epoch Biosciences, Inc. He is on the Board of Directors at Madrigal Pharmaceuticals, Inc., Dermira, Inc., Encarta, Inc., EOS Biotechnology, Inc., Incyte Genomics Inc. /Micoarray Operations/, Reset Therapeutics, Inc., Tallikut Pharmaceuticals, Inc., Twist Bioscience Corp. and Loyola Marymount University. Dr. Craves was previously employed as Chairman by Madrigal Pharmaceuticals, Inc. /Old/, Founder by Burrill & Craves, an Independent Director by Poniard Pharmaceuticals, Inc., President & Chief Executive Officer by Berlex Laboratories, Inc., President & Chief Executive Officer by Berlex Biosciences, Chairman & Chief Executive Officer by Codon, Co-Founder by Creative Biomolecules, Inc., Founder by Reliant Pharmaceuticals LLC, and Executive Vice President by Schering Berlin, Inc. He also served on the board at Synta Pharmaceuticals Corp., VIA Pharmaceuticals, Inc. /Old/, VIA Pharmaceuticals, Inc., BioSeek, Inc., Galileo Pharmaceuticals, Inc., GENTURAdx USA, Inc., Incyte Pharmaceuticals, Inc., Ion Torrent Systems, Inc. and Medarex, Inc. He received his undergraduate degree from Georgetown University, a graduate degree from The Wayne State University School of Medicine and a doctorate degree from The University of California, San Francisco.
David V. Milligan David V. Milligan founded Reliant Pharmaceuticals LLC. He is on the board of Madrigal Pharmaceuticals, Inc., Xoult, Inc. and Inspirotech Ltd. and Member-Chemical Sciences Leadership Council at the University of Illinois. Dr. Milligan previously was Chairman for Galileo Pharmaceuticals, Inc., Chief Scientific Officer & Senior Vice President at Abbott Laboratories, Vice President at Bay City Capital LLC and Director at Reliant Pharmaceuticals LLC. David V. Milligan received a doctorate and a graduate degree from the University of Illinois and an undergraduate degree from Princeton University.
Kenneth M. Bate Kenneth M. Bate is a businessperson who founded JSB-Partners LP and who has been the head of 6 different companies. Presently, he is Chairman for Catabasis Pharmaceuticals, Inc. and Chairman for Genocea Biosciences, Inc. Mr. Bate is also on the board of AVEO Pharmaceuticals, Inc., Epizyme, Inc. and Madrigal Pharmaceuticals, Inc. In his past career Kenneth M. Bate occupied the position of Chief Executive Officer of Mpm Capital LLC, Chief Financial Officer at Biogen, Inc. and Chief Financial Officer, VP-Sales & Marketing at Biogen MA, Inc. (a subsidiary of Biogen, Inc.), Partner at JSB-Partners LP, Lead Independent Director at Cubist Pharmaceuticals LLC, President, Chief Executive Officer & Director at Archemix Corp., President, Chief Executive Officer & Director at NitroMed, Inc. and CFO & Head-Commercial Operations at Takeda Oncology Co. Kenneth M. Bate received an undergraduate degree from Williams College and an MBA from The Wharton School of the University of Pennsylvania.
Paul A. Friedman Currently, Paul A. Friedman is Chairman, President & Chief Executive Officer of Madrigal Pharmaceuticals, Inc. He is also on the board of Incyte Corp. (former President, Chief Executive Officer & Director), Alexion Pharmaceuticals, Inc. and Gliknik, Inc. and Member of American Society for Pharmacology & Experimental Therapeutic, Member of American Society for Biochemistry & Molecular Biology, Inc. and Member of American Society for Clinical Investigation. He previously held the position of Director at Cerulean Pharma, Inc., President of DuPont Pharmaceuticals Research Laboratories, President-Research & Development at DuPont Merck Pharmaceutical Co., Senior Vice President of Merck Research Laboratories and Associate Professor at Harvard Medical School. Paul A. Friedman received an undergraduate degree from Princeton University and a doctorate from Harvard Medical School.
Richard S. Levy Richard S. Levy is on the board of Gliknik, Inc. and 4 other companies. Dr. Levy previously held the position of Chief Drug Development Officer & Executive VP at Incyte Corp., Vice President-Biologic Therapies at Celgene Corp., Principal at Sandoz Corp., Vice President-Regulatory Affairs at DuPont Pharmaceuticals Co. and Assistant Professor at David Geffen School of Medicine. He received an undergraduate degree from Brown University and a doctorate from Perelman School of Medicine.
Keith R. Gollust Currently, Keith R. Gollust occupies the position of President of Gollust Management, Inc. Mr. Gollust is also on the board of CastleLine Holdings LLC, The Juilliard School, Script Relief LLC and Madrigal Pharmaceuticals, Inc. and General Partner at Wyandanch Partners LP. In the past Keith R. Gollust held the position of Managing Director at Caxton Associates LP and Chairman at Synta Pharmaceuticals Corp. Mr. Gollust received an undergraduate degree from Princeton University and a graduate degree from Carnegie Mellon University.
Marc R. Schneebaum Currently, Marc R. Schneebaum holds the position of CFO, Principal Accounting Officer & Senior VP at Madrigal Pharmaceuticals, Inc. Mr. Schneebaum is also on the board of Stemina Biomarker Discovery, Inc. Mr. Schneebaum previously held the position of President, Chief Executive Officer & Director at Predictive Biosciences, Inc., President, Chief Executive Officer & Director at Senseonics, Inc., Chief Financial Officer & Senior VP-Administration at Genetic Therapy, Inc., Senior VP, Chief Financial & Accounting Officer at Synta Pharmaceuticals Corp., Vice President at Alex. Brown & Sons, Inc. and Senior Manager at KPMG LLP. Marc R. Schneebaum received an undergraduate degree from the University of Maryland.
Brian J. Lynch Brian J. Lynch is Senior Vice President & General Counsel at Madrigal Pharmaceuticals, Inc. In his past career he occupied the position of Corporate Officer at Hogan & Hartson LLP.
Rebecca A. Taub Dr. Rebecca A. Taub, MD, is an Independent Director at BriaCell Therapeutics Corp. and a Director & President-Research & Development at Madrigal Pharmaceuticals, Inc. She is on the Board of Directors at BriaCell Therapeutics Corp. and Madrigal Pharmaceuticals, Inc. Dr. Taub was previously employed as a Chief Executive Officer & Director by Madrigal Pharmaceuticals, Inc. /Old/, a Senior Vice President-Research & Development by VIA Pharmaceuticals, Inc., a Vice President-Research & Metabolic Diseases by Hoffmann-La Roche, Inc., a Vice President-Research by Roche Pharmaceuticals, Inc., an Executive Director-CNS & Obesity Research by Bristol-Myers Squibb Co., an Executive Director-CNS & Obesity Research by DuPont Pharmaceuticals Co., a Professor by Perelman School of Medicine, an Assistant Professor by Harvard Medical School, an Associate Investigator by Howard Hughes Medical Institute, Inc., and a Professor by University of Pennsylvania. She received her undergraduate degree from Yale College and a doctorate degree from Yale School of Medicine.
James M. Daly James M. Daly is on the board of ACADIA Pharmaceuticals, Inc. and 6 other companies. In the past Mr. Daly held the position of Chief Commercial Officer & Executive VP at Incyte Corp., Principal at Francis Cauffman, Inc., SVP-Global Marketing & Commercial Development at Amgen, Inc. and Senior Vice President of Amgen Ventures LLC (a subsidiary of Amgen, Inc.) and SVP, General Manager-Respiratory & Anti Infectives at GlaxoSmithKline LLC. He received an MBA from The State University of New York and an MBA and an undergraduate degree from State University of New York at Buffalo.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐